Logo

American Heart Association

  21
  0


Final ID: Sa3104

Inactive Matrix Gla Protein and Cardiovascular Outcomes: the Multi-Ethnic Study of Atherosclerosis

Abstract Body (Do not enter title and authors here): Background: Matrix Gla protein (MGP) inhibits arterial calcification. Higher inactive MGP, dephosphorylated-uncarboxylated (dp-ucMGP), is positively associated with vascular calcification, possibly portending cardiovascular events. The objective was to determine the association of dp-ucMGP with incident cardiovascular disease (CVD) events and mortality in the Multi-Ethnic Study of Atherosclerosis (MESA).
Methods: MESA is a cohort study of 45-84 year-old individuals enrolled between 2000-02 with adjudicated outcomes through 2019. Dp-ucMGP was measured at baseline in n=2663 participants with cardiac computed tomography at Exams 1 (2000-02) and 5 (2010-12). Using age-stratified Cox proportional hazard models, adjusted for sex, race-ethnicity, body mass index, systolic blood pressure, statin use, anti-hypertensive medication use, smoking status, physical activity, alcohol use, diabetes, high density lipoprotein, low density lipoprotein, triglycerides, phosphate, and estimated glomerular filtration rate, we determined the association of dp-ucMGP with risk of all CVD (mean follow-up 16 + 4 years), hard CVD (17 + 3 years), hard CHD (17 + 3 years), and all-cause mortality (18 + 2 years).
Results: The youngest age quartile (45-53-years-old) with higher dp-ucMGP levels (520-2934 pmol/L) had an increased risk of all CVD (HR 3.01 [95% CI 1.56, 5.80], p=0.001), hard CVD (HR 2.78 [95% CI 1.29, 6.02], p=0.009), hard CHD (HR 3.37 [95% CI 1.29, 8.81], p=0.013) and all-cause mortality (HR 2.69 [95% CI 1.06, 6.79], p=0.037) compared to dp-ucMGP levels between 150-519 pmol/L in maximally adjusted models. There was no relationship with any outcomes for the other age quartiles (Table).
Conclusions: Middle aged individuals with elevated dp-ucMGP levels (>520 pmol/L) had an increased risk of incident CVD, CHD, and all-cause mortality.
  • Berlot, Ashley  ( Albert Einstein College of Medicine , Bronx , New York , United States )
  • Bortnick, Anna  ( WEILER HOSP , Bronx , New York , United States )
  • Fu, Xueyan  ( TUFTS UNIVERSITY , Boston , Massachusetts , United States )
  • Shea, Kyla  ( TUFTS UNIVERSITY , Boston , Massachusetts , United States )
  • Tracy, Russell  ( UNIVERSITY VERMONT , Colchester , Vermont , United States )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Kim, Ryung  ( Albert Einstein College of Medicine , Bronx , New York , United States )
  • Naveed, Mahim  ( San Francisco VA , San Francisco , California , United States )
  • Booth, Sarah  ( Tufts University , Boston , Massachusetts , United States )
  • Kizer, Jorge  ( San Francisco VA , San Francisco , California , United States )
  • Author Disclosures:
    Ashley Berlot: DO NOT have relevant financial relationships | Anna Bortnick: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Getinge, Honoraria to Institution:Past (completed) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):CSL Behring:Past (completed) ; Other (please indicate in the box next to the company name):Zoll, Honoraria to Institution:Past (completed) | Xueyan Fu: DO NOT have relevant financial relationships | Kyla Shea: DO NOT have relevant financial relationships | Russell Tracy: No Answer | Matthew Budoff: DO have relevant financial relationships ; Researcher:General Electric:Active (exists now) | Ryung Kim: No Answer | Mahim Naveed: DO NOT have relevant financial relationships | Sarah Booth: No Answer | JORGE KIZER: DO have relevant financial relationships ; Individual Stocks/Stock Options:Abbott:Past (completed) ; Individual Stocks/Stock Options:Pfizer:Past (completed) ; Individual Stocks/Stock Options:Merck:Past (completed) ; Individual Stocks/Stock Options:Medtronic:Past (completed) ; Individual Stocks/Stock Options:Lilly:Past (completed) ; Individual Stocks/Stock Options:Johnson & Johnson:Past (completed) ; Individual Stocks/Stock Options:Bristol Myers Squibb:Past (completed) ; Individual Stocks/Stock Options:AbbVie:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Clinical Prediction, Prognosis, and Decision-Making

Saturday, 11/16/2024 , 02:00PM - 03:00PM

Abstract Poster Session

More abstracts on this topic:
ADC-based Infarct Density – Validating a Novel Imaging Biomarker of Functional Outcome after Endovascular Thrombectomy

Favilla Christopher, Bonkhoff Anna, Rost Natalia, Messe Steven, Regenhardt Robert, Denny Braden, Simonsen Claus, Shakibajahromi Banafsheh, Patel Aman, Leslie-mazwi Thabele, Dmytriw Adam, Schirmer Markus

A Measure of Residential Segregation and Thrombo-inflammation in Black and White Americans

Manogaran Erin, Cushman Mary, Kamin Mukaz Debora, Sparks Andrew, Packer Ryan, Brochu Paige, Judd Suzanne, Howard Virginia, Plante Timothy, Long Leann, Cheung Katherine

You have to be authorized to contact abstract author. Please, Login
Not Available